Revtorpyk cleared for HR+/HER2-, PIK3CA wild-type breast cancer

What this means

Revtorpyk is a cancer drug that works by blocking two key proteins, PI3K and mTOR, which help cancer cells grow. Today FDA approved Revtorpyk for patients with advanced breast cancer that is hormone receptor-positive, HER2-negative, and lacks a specific mutation called PIK3CA. This approval gives patients with this specific cancer type a new treatment option that targets their disease’s underlying biology.